Lab-Grown Meat Soon on Australia's Menus After Approval
Australia has approved the sale of slaughter-free Japanese quail, becoming only the third country in the world to permit the sale of meat cultivated from animal cells.
Sydney-based startup Vow will offer products made from quail cells at local restaurants within weeks, it said in a statement. That follows an amendment to Australia's food standards code published Wednesday after a years-long assessment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
The Boeing Company (BA) Announces First of its Kind Demonstration
The Boeing Company (NYSE:BA) is one of the 13 Best Aerospace and Defense Stocks to Invest in Now. On June 16, The Boeing Company (NYSE:BA) in collaboration with Royal Australian Air Force announced a successful first-of-its-kind demonstration. Under the demonstration, two uncrewed MQ-28 Ghost Bat aircraft, along with a third digital aircraft, were controlled simultaneously by a single operator aboard an airborne E-7A Wedgetail surveillance aircraft. The MQ-28s acted as forward escorts, flying ahead of and protecting crewed assets, showcasing their role as collaborative combat aircraft that can expand and enhance the operational capabilities of the E-7A Wedgetail. A modern commercial jetliner in flight, its wings capturing the gleam of the sunlight. The trial validated a critical interoperability requirement, proving the ability to integrate mission partners' software and communication systems natively into the E-7A Wedgetail's open systems architecture. Moreover, the software enabling this integration was developed collaboratively by The Boeing Company (NYSE:BA) Defence Australia, the Defence Science and Technology Group, and the US Air Force Research Laboratories. The Boeing Company (NYSE:BA) is a leading aerospace company that designs, manufactures, and sells commercial jet aircraft. It also develops and produces manned and unmanned military aircraft, weapons systems, and space technologies. While we acknowledge the potential of BA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
The Boeing Company (BA) Announces First of its Kind Demonstration
The Boeing Company (NYSE:BA) is one of the 13 Best Aerospace and Defense Stocks to Invest in Now. On June 16, The Boeing Company (NYSE:BA) in collaboration with Royal Australian Air Force announced a successful first-of-its-kind demonstration. Under the demonstration, two uncrewed MQ-28 Ghost Bat aircraft, along with a third digital aircraft, were controlled simultaneously by a single operator aboard an airborne E-7A Wedgetail surveillance aircraft. The MQ-28s acted as forward escorts, flying ahead of and protecting crewed assets, showcasing their role as collaborative combat aircraft that can expand and enhance the operational capabilities of the E-7A Wedgetail. A modern commercial jetliner in flight, its wings capturing the gleam of the sunlight. The trial validated a critical interoperability requirement, proving the ability to integrate mission partners' software and communication systems natively into the E-7A Wedgetail's open systems architecture. Moreover, the software enabling this integration was developed collaboratively by The Boeing Company (NYSE:BA) Defence Australia, the Defence Science and Technology Group, and the US Air Force Research Laboratories. The Boeing Company (NYSE:BA) is a leading aerospace company that designs, manufactures, and sells commercial jet aircraft. It also develops and produces manned and unmanned military aircraft, weapons systems, and space technologies. While we acknowledge the potential of BA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
6 hours ago
- Yahoo
Can Camp4 Therapeutics (NASDAQ:CAMP) Afford To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse. Given this risk, we thought we'd take a look at whether Camp4 Therapeutics (NASDAQ:CAMP) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. First, we'll determine its cash runway by comparing its cash burn with its cash reserves. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. A company's cash runway is calculated by dividing its cash hoard by its cash burn. As at March 2025, Camp4 Therapeutics had cash of US$49m and such minimal debt that we can ignore it for the purposes of this analysis. Importantly, its cash burn was US$49m over the trailing twelve months. So it had a cash runway of approximately 12 months from March 2025. That's quite a short cash runway, indicating the company must either reduce its annual cash burn or replenish its cash. Depicted below, you can see how its cash holdings have changed over time. See our latest analysis for Camp4 Therapeutics In our view, Camp4 Therapeutics doesn't yet produce significant amounts of operating revenue, since it reported just US$1.5m in the last twelve months. As a result, we think it's a bit early to focus on the revenue growth, so we'll limit ourselves to looking at how the cash burn is changing over time. With the cash burn rate up 15% in the last year, it seems that the company is ratcheting up investment in the business over time. However, the company's true cash runway will therefore be shorter than suggested above, if spending continues to increase. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years. Since its cash burn is moving in the wrong direction, Camp4 Therapeutics shareholders may wish to think ahead to when the company may need to raise more cash. Companies can raise capital through either debt or equity. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate). Since it has a market capitalisation of US$30m, Camp4 Therapeutics' US$49m in cash burn equates to about 165% of its market value. That suggests the company may have some funding difficulties, and we'd be very wary of the stock. Camp4 Therapeutics is not in a great position when it comes to its cash burn situation. Although we can understand if some shareholders find its cash runway acceptable, we can't ignore the fact that we consider its cash burn relative to its market cap to be downright troublesome. Considering all the measures mentioned in this report, we reckon that its cash burn is fairly risky, and if we held shares we'd be watching like a hawk for any deterioration. Separately, we looked at different risks affecting the company and spotted 6 warning signs for Camp4 Therapeutics (of which 2 are a bit unpleasant!) you should know about. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies with significant insider holdings, and this list of stocks growth stocks (according to analyst forecasts) — Investing narratives with Fair Values A case for TSXV:USA to reach USD $5.00 - $9.00 (CAD $7.30–$12.29) by 2029. By Agricola – Community Contributor Fair Value Estimated: CA$12.29 · 0.9% Overvalued DLocal's Future Growth Fueled by 35% Revenue and Profit Margin Boosts By WynnLevi – Community Contributor Fair Value Estimated: $195.39 · 0.9% Overvalued Historically Cheap, but the Margin of Safety Is Still Thin By Mandelman – Community Contributor Fair Value Estimated: SEK232.58 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
